# Organoid-guided evidence that umbilical cord MSC-derived extracellular vesicles restore alveolar repair in cigarette smoke-induced lung injury

**Authors:** Syahidatulamali Che Shaffi, Anan A. Ishtiah, Azim Patar, Badrul Hisham Yahaya

PMC · DOI: 10.3389/fcell.2026.1710021 · 2026-03-17

## TL;DR

This study shows that extracellular vesicles from umbilical cord stem cells can help repair lung damage caused by cigarette smoke, offering a potential new treatment for COPD.

## Contribution

The study introduces a novel organoid-guided approach to demonstrate that hUC-MSC-derived EVs restore alveolar repair in cigarette smoke-induced lung injury.

## Key findings

- EV treatment reduced inflammation and collagen deposition in CS-injured lungs.
- EVs normalized organoid number and size and restored AT2/AT1 lineage balance.
- EVs modulated key pathways like IL-17 and PI3K–AKT–mTOR to promote epithelial homeostasis.

## Abstract

Chronic cigarette smoke (CS) disrupts epithelial homeostasis, fuels persistent inflammation, and impairs alveolar repair—hallmarks of COPD with few disease-modifying options. Extracellular vesicles (EVs) from human umbilical cord mesenchymal stem cells (hUC-MSCs) are emerging as cell-free modulators of regeneration, yet their impact on the CS-injured alveolus and alveolar type-2 (AT2) stem/progenitor programs remains unclear. We used a preclinical model of chronic CS exposure coupled with organoid-guided analyses to test whether hUC-MSC-derived EVs can restore epithelial regeneration while tempering injury-associated inflammation and remodeling. Following CS injury, animals received vehicle, hUC-MSCs, or purified hUC-MSC EVs; lungs were evaluated histologically (airway/parenchymal inflammation, emphysema-like change), by Masson’s trichrome (collagen deposition), and functionally using ex vivo epithelial organoids (organoid number/size, architecture, and AT2/AT1 marker balance). Transcriptomic profiling of organoid-derived RNA mapped pathway-level changes. CS induced robust immune-cell infiltration, increased collagen, and abnormal organoid phenotypes consistent with dysregulated progenitor activity. Post-injury EV treatment reduced inflammatory infiltrates and collagen, normalized organoid number and size, and restored AT2/AT1 lineage balance toward naïve patterns. At the molecular level, EVs dampened injury-upregulated circuits (including IL-17, PI3K–AKT–mTOR, MAPK, oxidative-stress and matrix-remodeling signatures) and enriched pathways associated with epithelial homeostasis and barrier integrity. Together, these data position hUC-MSC EVs as precision modulators of the injured alveolar niche that rebalance inflammation and re-engage endogenous regenerative programs. The organoid-guided, multi-scale readouts provide mechanistic insight and a translational rationale for EV-based regenerative therapeutics in smoke-induced lung injury and, by extension, COPD.

Integrative model summarizing the effects of chronic cigarette smoke exposure on lung inflammation, alveolar injury, dysregulated alveolar stem cell regeneration, and possible malignant transition toward lung cancer development.Diagram illustrating chronic cigarette smoke exposure leading to alveolar destruction, inflammation, and collagen deposition in a murine COPD model, resulting in impaired differentiation and abnormal lung organoid proliferation involving IL-17A signaling, PI3K-Akt-mTOR pathway, and matrix metalloproteinases.

Integrative model summarizing the effects of chronic cigarette smoke exposure on lung inflammation, alveolar injury, dysregulated alveolar stem cell regeneration, and possible malignant transition toward lung cancer development.

## Linked entities

- **Proteins:** IL17A (interleukin 17A), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), AKT1 (AKT serine/threonine kinase 1), MTOR (mechanistic target of rapamycin kinase)
- **Diseases:** COPD (MONDO:0005002), lung cancer (MONDO:0005138)

## Full-text entities

- **Genes:** PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}
- **Diseases:** emphysema (MESH:D004646), lung injury (MESH:D055370), inflammation (MESH:D007249), COPD (MESH:D029424)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13036102/full.md

---
Source: https://tomesphere.com/paper/PMC13036102